Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 23, Issue 3, Pages 305-315Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2014.871259
Keywords
angiogenesis; cediranib; dovitinib; drug resistance; fibroblast growth factor pathway; lenvatinib; nintedanib; regorafenib; renal cell carcinoma
Categories
Funding
- Novartis Pharmaceuticals Corp.
- Novartis
Ask authors/readers for more resources
Introduction: Metastatic clear-cell renal cell carcinoma (RCC) is a highly vascularized tumor type that is often associated with inactivating mutations in the von Hippel-Lindau gene that ultimately drives pro-angiogenic signaling pathways, including the VEGF pathway. As such, new therapies indicated for RCC have largely focused on blocking angiogenesis by inhibiting this pathway. Despite the contribution of these agents to clinical outcomes in RCC, acquired resistance that stimulates tumor regrowth and revascularization quickly emerges. Resistance to VEGF inhibition appears to largely result from activation of compensatory angiogenesis pathways (including the fibroblast growth factor [FGF] pathway), providing a rationale to investigate their inhibition. Areas covered: This review explores the role of the FGF pathway in resistance to VEGF-targeted therapy and rationale for targeting in RCC. PubMed, as well as ASCO and ESMO congress abstracts, were searched for preclinical and clinical data for FGF inhibitors in RCC. Expert opinion: The FGF pathway presents a logical target in RCC and trials of the FGF receptor inhibitors regorafenib, dovitinib, nintedanib, lenvatinib and cediranib demonstrated clinical activity. Clinical development should focus on optimizing the use of this therapy by improving patient selection and evaluating combined therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available